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The World Health Organization (WHO) currently recommends that HIV-positive adults start antiretroviral therapy (ART) at 
CD4 counts <350 cells/µl. Several countries have changed their guidelines to recommend ART irrespective of CD4 count or at a 
threshold of 500 CD4 cells/µl. Consequently, WHO is currently revising its treatment guidelines and considering recommending 
ART initiation at CD4 counts <500 cells/µl. Such decisions are critically important, as WHO guidelines inform healthcare 
policies in developing countries and are used by activists in their advocacy work. Changing the CD4 initiation point from 350 
to 500 cells/µl would, however, be premature and have profound cost implications on Global Fund, President’s Emergency Plan 
for AIDS Relief (PEPFAR) and developing country health budgets. We should be willing to campaign for such a change in 
guidelines despite cost implications, if supported by evidence. However, the evidence remains outstanding.
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The World Health Organization (WHO) currently recommends 
that adults living with HIV start antiretroviral therapy (ART) 
when their CD4 counts fall below 350 cells/µl. Several countries 
have changed their ART guidelines to recommend treatment 
irrespective of CD4 count or at treatment thresholds of 500 CD4 
cells/µl.[1] WHO is currently revising its treatment guidelines and 
considering recommending that treatment start at 500 cells/µl. 
The decisions taken by WHO on ART guidelines are extremely 
important, as these guide healthcare policies in developing 
countries and are used by activists in their advocacy work.
To understand the impact of the WHO guidelines, it is 
important to consider that there are more people living with 
HIV in Nigeria alone than in the whole of North America, 
Western Europe and Australia combined. Even a small country 
such as Zimbabwe has more HIV-positive people than in 
the whole of Western Europe.[2] Countries in sub-Saharan 
Africa, the Caribbean and Asia are strongly influenced by the 
WHO guidelines, much more so than by the Department of 
Health and Human Services (DHHS) guidelines published 
in the United States of America. This is especially the case 
for countries where treatment is primarily provided through 
funding from the Global Fund to Fight AIDS, TB and Malaria 
(GFATM) or the United States President’s Emergency Plan For 
AIDS Relief (PEPFAR).
The evidence for changing 
CD4 initiation thresholds
When considering changing the CD4 threshold for ART 
initiation, or dispensing a threshold entirely, we need to 
consider the evidence to support such a change, for both an 
individual patient’s health and for HIV prevention efforts at a 
population level.
Prevention
The HPTN 052 trial showed that ART greatly reduces the risk 
of an HIV-positive person transmitting HIV to his/her partner. 
This finding was consistent with compelling observational 
data. [3] There is also evidence from several places, including San 
Francisco, Vancouver and Taiwan, that reducing community 
viral load reduces HIV incidence.[4-6] There is also indication from 
mathematical models that ART may be reducing HIV incidence 
in South Africa.[7] WHO subsequently published guidelines 
regarding the role of ART in HIV prevention efforts.[8]
Nevertheless, in many settings it is not clear whether 
changing the CD4 initiation threshold to 500 CD4 cell/ µl 
would have a significant effect on HIV incidence. In contrast 
to places in North America where reduction in community 
viral load has been shown to reduce incidence, the distribution 
of HIV in many sub-Saharan African cities is characterised 
largely by heterosexual epidemics of a much broader scale. 
It is likely that reducing viral load through widespread ART 
use will reduce incidence in sub-Saharan Africa, but this 
is not a given. Moreover, this approach has to be proven to 
policy makers, because there are enormous cost implications 
associated with this type of expanded treatment. Studies 
currently underway in African countries are looking at 
whether initiating treatment earlier does reduce community 
incidence.






The benefit to the patient should be the salient consideration in 
the WHO treatment guidelines (as opposed to guidelines for sero-
discordant couples, where preventing infection of the HIV-negative 
partner is the primary consideration). When empirical data on this 
question are appraised rigorously, as in the British HIV Association’s 
guidelines, it emerges that the evidence for initiating treatment at a CD4 
count >350 cells/µl is poor.[9]
One widely circulated myth that needs to be discredited is that the 
HPTN 052 trial showed a reduced disease progression when ART was 
initiated above 350 CD4 cells/µl: the initiation threshold was 250 CD4 
cells/µl, and not 350 cells/µl. Data from clinical trials had previously shown 
that a treatment threshold of 250 cells/µl was inferior.[10,11] The question of 
whether a threshold of 350 CD4 cells/µl is optimal remains unanswered.
Guidelines in some wealthy countries have changed to-and-fro over 
the last decade and a half on the issue of when to initiate ART: from the 
‘hit hard, hit early’ strategy promoted in the 1990s, to postponing ART 
initiation until lower CD4 thresholds more recently. This is precisely 
why the Strategic Timing of Anti Retroviral Therapy trial (START) 
(funded by the United States National Institute of Health) and the Early 
Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against 
Tuberculosis in HIV-positive Adults trial (TEMPRANO) (funded by 
the French National Agency for Research on AIDS and Viral Hepatitis) 
are being conducted: to answer once and for all when the best point is 
for patients to start ART. 
There are three likely outcomes of the START and TEMPRANO 
studies: (i) that earlier treatment reduces disease progression; (ii) that 
there is no difference between the earlier v. later treatment arms; or 
(iii) that earlier treatment is harmful due to increased side-effects 
or reduced adherence. If the latter two outcomes emerge but WHO 
has already recommended earlier treatment, it will undermine the 
WHO treatment guidelines in general. At best, there would have been 
serious cost implications for developing country health budgets; and at 
worst patients might have been harmed. If WHO keeps its threshold 
recommendation unchanged and the first of the aforementioned 
outcomes is validated, then the organisation would have taken the 
correct action by having waited for the evidence. 
Although clinicians and AIDS activists have different expectations of 
the trial results, these personal prejudices do not matter. The evidence is 
simply not yet available, and in this case, WHO needs to wait.
The issue of cost
Cost is profoundly important when considering public health 
interventions, and should always be a concern for activists. To ignore 
such implications is poor activism, not only because policy makers 
do not take activists who ignore cost seriously, but also because it is 
morally problematic. Public health policy involves making choices 
determined by cost. As ART becomes more nuanced, the relative cost 
per disability adjusted life-year (DALY) saved becomes higher and the 
arguments for using the money elsewhere become harder to refute. As 
an example of how cost has informed activism in a developing country, 
the Treatment Action Campaign (TAC) has been cognisant of cost in its 
campaigns, despite demanding that the South African (SA) government 
implements treatment and prevention programmes. In a court case that 
dealt with prevention of mother-to-child transmission of HIV in 2002, 
the TAC included an affidavit that showed that the intervention would 
be cost-saving.[12] The TAC later published research showing that ART 
would be affordable for the SA government.  By considering cost, the 
TAC was able to make compelling arguments for the implementation of 
life-saving interventions.
The current WHO ART guidelines for adults and adolescents include 
two important changes, including provision (i) for ART to be initiated 
at 350 CD4 cells/µl; and (ii) for stavudine (d4T) to be replaced by 
tenofovir (TDF). Both of these changes have cost implications, but 
are supported by a very strong evidence base. Because the campaigns 
for these changes to be adopted by poor countries have been based on 
sound science, they have met some success. WHO guidelines should 
be seen as an achievable aspiration for poorer countries. Nevertheless, 
even today, several sub-Saharan countries initiate ART at 200 - 250 
CD4 cells/µl with stavudine, largely due to resource limitations. This 
proves that cost is a critical factor – perhaps the most critical factor – in 
getting poorer countries to change their guidelines.
Conclusion
Changing the CD4 initiation point from 350 to 500 cells/µl in the 
new WHO guidelines would be premature. It would have profound 
cost implications on Global Fund, PEPFAR and developing country 
health budgets. We should be willing to campaign for such a change in 
guidelines despite cost implications if it was supported by evidence. But, 
the evidence is still outstanding. Expecting countries to move to a costly 
new CD4 threshold without sufficient evidence is a mistake.
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